IPP Bureau
Moderna announces promising efficacy results from mRNA flu vaccine trial
By IPP Bureau - July 01, 2025
mRNA-1010 demonstrated superior relative vaccine efficacy
Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery
By IPP Bureau - July 01, 2025
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
PerkinElmer appoints Payal Agrawaal as MD - India & South Asia
By IPP Bureau - July 01, 2025
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Briefs: Lyfius Pharma and Aurobindo Pharma
By IPP Bureau - July 01, 2025
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
Indegene identified as leader in ISG's Provider Lens for life sciences digital services
By IPP Bureau - July 01, 2025
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Biocon Biologics expands insulin access in Malaysia
By IPP Bureau - June 30, 2025
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market
By IPP Bureau - June 30, 2025
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Briefs: Neuland Laboratories and Granules India
By IPP Bureau - June 29, 2025
Granules India receives 1 observation from USFDA for Chantilly facility
Alembic announces USFDA final approval for single-dose vials
By IPP Bureau - June 29, 2025
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
By IPP Bureau - June 29, 2025
Extended lab space for product development, customer demos, and training
Zambon launches intravenous formulation of Fluimucil
By IPP Bureau - June 29, 2025
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr
By IPP Bureau - June 29, 2025
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Shukra Pharmaceuticals receives LoA from RMSCL
By IPP Bureau - June 28, 2025
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME
By IPP Bureau - June 28, 2025
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels
By IPP Bureau - June 28, 2025
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
